中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2014年
8期
121-123
,共3页
替吉奥%同步放化疗%晚期复发性食管癌
替吉奧%同步放化療%晚期複髮性食管癌
체길오%동보방화료%만기복발성식관암
S-1%Concurrent chemoradiotherapy%Advanced recurrent nasopharyngeal carcinoma
目的：探讨替吉奥在晚期复发性食管癌治疗中的临床疗效和不良反应。方法将80例晚期复发性食管癌患者采用数字随机法分为治疗组和对照组，每组各40例。首先对两组患者进行放疗，随后治疗组患者采用替吉奥方案治疗，第1天和第8天静脉滴注替吉奥1000 mg/m2＋生理盐水100 ml，滴注6小时。对照组患者采用氟尿嘧啶联合奈达铂治疗，第1～5天每日静脉滴注20～30 mg/kg氟尿嘧啶，第1～3天每日静脉滴注奈达铂25 mg/m2。一周期为21天，所有患者至少完成3个周期的治疗。结果治疗组患者完全缓解6例，部分缓解25例，稳定5例，进展4例，总有效率为77.5%；对照组患者完全缓解4例，部分缓解21例，稳定9例，进展6例，总有效率为62.5%。常见不良反应为中性粒细胞减少、血小板减少和血红蛋白减少，呕吐、肝肾损坏症状较轻，对照组患者恶心呕吐发生率明显高于治疗组（P＜0.05），治疗组患者血小板减少发生率高于对照组（P＜0.05）。结论替吉奥治疗复发性食管癌疗效较好，不良反应较轻，适合临床推广应用。
目的：探討替吉奧在晚期複髮性食管癌治療中的臨床療效和不良反應。方法將80例晚期複髮性食管癌患者採用數字隨機法分為治療組和對照組，每組各40例。首先對兩組患者進行放療，隨後治療組患者採用替吉奧方案治療，第1天和第8天靜脈滴註替吉奧1000 mg/m2＋生理鹽水100 ml，滴註6小時。對照組患者採用氟尿嘧啶聯閤奈達鉑治療，第1～5天每日靜脈滴註20～30 mg/kg氟尿嘧啶，第1～3天每日靜脈滴註奈達鉑25 mg/m2。一週期為21天，所有患者至少完成3箇週期的治療。結果治療組患者完全緩解6例，部分緩解25例，穩定5例，進展4例，總有效率為77.5%；對照組患者完全緩解4例，部分緩解21例，穩定9例，進展6例，總有效率為62.5%。常見不良反應為中性粒細胞減少、血小闆減少和血紅蛋白減少，嘔吐、肝腎損壞癥狀較輕，對照組患者噁心嘔吐髮生率明顯高于治療組（P＜0.05），治療組患者血小闆減少髮生率高于對照組（P＜0.05）。結論替吉奧治療複髮性食管癌療效較好，不良反應較輕，適閤臨床推廣應用。
목적：탐토체길오재만기복발성식관암치료중적림상료효화불량반응。방법장80례만기복발성식관암환자채용수자수궤법분위치료조화대조조，매조각40례。수선대량조환자진행방료，수후치료조환자채용체길오방안치료，제1천화제8천정맥적주체길오1000 mg/m2＋생리염수100 ml，적주6소시。대조조환자채용불뇨밀정연합내체박치료，제1～5천매일정맥적주20～30 mg/kg불뇨밀정，제1～3천매일정맥적주내체박25 mg/m2。일주기위21천，소유환자지소완성3개주기적치료。결과치료조환자완전완해6례，부분완해25례，은정5례，진전4례，총유효솔위77.5%；대조조환자완전완해4례，부분완해21례，은정9례，진전6례，총유효솔위62.5%。상견불량반응위중성립세포감소、혈소판감소화혈홍단백감소，구토、간신손배증상교경，대조조환자악심구토발생솔명현고우치료조（P＜0.05），치료조환자혈소판감소발생솔고우대조조（P＜0.05）。결론체길오치료복발성식관암료효교호，불량반응교경，괄합림상추엄응용。
Objective To explore the effect of S-1 and concurrent chemoradiotherapy in the treatment of advanced esophageal cancer. Method 80 cases of patients with advanced recurrent esophageal cancer were randomly divided into treatment group and control group, 40 cases in each group. First of two groups of patients with radiation therapy, then for S-1 treatment, they were treated by 1 and 8 days intravenous drip for S-1 1000 mg/m2 and physiological saline 100 ml, drip 6 hours. The control group were treated by combined therapy with nedaplatin and lfuorouracil, 1~5 days intravenous drip 20~30 mg/kg lfuorouracil, 1~3 days intravenous drip nedaplatin 25 mg/m2. A cycle for 21 days, all patients completed at least three cycles of treatment. Result 6 cases of treatment group patients with complete remission, partial remission in 25 cases, stable in 5 cases, and 4 cases of progress. The total effective rate was 77.5%;control group patients with complete remission in 4 cases, partial in 21 cases, 9 cases of stability and progress in 6 cases. The total effective rate was 62.5%. The common adverse reactions as neutropenia, thrombocytopenia and hemoglobin decreased. Vomiting, liver and kidney damage symptoms lighter, incidence of nausea and vomiting was signiifcantly higher in control group patients in treatment group (P<0.05), treatment group patients with thrombocytopenia was higher than control group (P<0.05). Conclusion S-1 treatment for recurrent esophageal cancer curative effect is good, adverse reaction is lighter, and suitable for clinical application.
